Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 42.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,082 shares of the medical research company’s stock after selling 67,034 shares during the period. Mackenzie Financial Corp’s holdings in Edwards Lifesciences were worth $7,021,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. Castleview Partners LLC acquired a new position in Edwards Lifesciences during the first quarter worth $25,000. Compass Wealth Management LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at $31,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at $34,000. Janiczek Wealth Management LLC grew its holdings in Edwards Lifesciences by 108.6% in the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 303 shares during the last quarter. Finally, Operose Advisors LLC grew its holdings in Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the transaction, the vice president now directly owns 39,503 shares in the company, valued at approximately $3,390,542.49. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, VP Donald E. Bobo, Jr. sold 11,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total transaction of $944,130.00. Following the transaction, the vice president now directly owns 39,503 shares of the company’s stock, valued at approximately $3,390,542.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now directly owns 173,849 shares in the company, valued at $16,049,739.68. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock worth $17,166,254 in the last three months. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE EW opened at $85.94 on Friday. The business’s 50-day moving average price is $90.15 and its 200 day moving average price is $78.37. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a market capitalization of $51.73 billion, a PE ratio of 37.37, a price-to-earnings-growth ratio of 4.29 and a beta of 1.05. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting analysts’ consensus estimates of $0.64. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period last year, the business posted $0.64 EPS. On average, research analysts predict that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Mizuho upped their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Wells Fargo & Company raised Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 target price on the stock in a report on Friday, February 2nd. Evercore ISI increased their price objective on Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Finally, Oppenheimer increased their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $91.73.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.